Enteral Feeding Devices Market Analysis

Enteral Feeding Devices Market Analysis

The enteral feeding tubes segment accounted for USD 2.12 billion in 2020 led by the growing acceptance of enteral feeding therapy coupled with rising incidences of chronic ailments across the globe. Increasing prevalence of conditions such as pre-mature births, malnutrition, neuromuscular and neurologic ailments, cancer and digestive disorders among others have surged the demand for enteral feeding tubes. Additionally, the Global Enteral Device Supplier Association (GEDSA) has announced introduction of novel enteral connectors (ENFit) that comply with the revised ISO standards. Development of this connector has promoted patient safety and reduced the occurrence of misconnection associated with enteral feeding tubes.

The adult segment dominated more than 60% of revenue share in 2020 on account of the rising geriatric population base and high incidence of conditions challenging oral intake in adult population. According to the World Health Organization (WHO), there are approximately 727 million people belonging to 65 years and older age group and the number is poised to double by 2050, accounting for more than 1.5 billion people globally. The incidence of conditions such as cerebral vascular disorders, dysphagia, neuro-degenerative diseases is reported high amongst elderly population. These conditions result in malnutrition, thereby generating high requirement for enteral nutrition for maintaining necessary calorie intake along with other fluids and medications. Thus, rising incidence of several health conditions resulting in malnutrition and growing geriatric population will amplify the industry revenue.

The cancer segment in the enteral feeding devices market captured 45% of revenue share in 2020 impelled by the growing prevalence of cancer, specifically head & neck, gastrointestinal, lung and liver cancer among others. Cancer and its treatment cause drastic alterations including malnutrition that may develop into cancer cachexia. As per the Malnutrition Advisory Action Group of the British Association for Parenteral and Enteral Nutrition, malnutrition is prevalent in 40% to 80% of cancer patients and is highly responsible for associated morbidity and mortality. The rising prevalence of cancer is set to play anchoring role in growing demand for these devices to offer vital nutrition to cancer patients.

The enteral feeding devices market for home care segment exceeded USD 2.44 billion in 2020 owing to increasing adoption of enteral feeding devices in the home care settings. Rising pressure to limit increasing healthcare expenses, significant advancements and availability of easy to use feeding equipment and favourable reimbursement scenario for home enteral nutrition (HEN) would further fuel the segment growth. Moreover, the COVID-19 pandemic has further increased the usage of enteral feeding devices in home care settings, thereby boosting the market growth in the coming years.
 

U.S. dominated the North American enteral feeding devices market and is slated to reach USD 2.22 billion by 2027. The significant market share is attributable to several factors such as high acceptance of enteral feeding devices in the home care settings, rise in incidence of chronic ailments and growing number of premature births across the country. Premature births and related complications are leading cause of death among babies in the U.S. Approximately 380,000 babies in the U.S. are born as premature on annual basis and the premature birth rate is around 9.8%. Babies that survive premature birth face long-term health concerns such as cerebral palsy, stunted growth and malnutrition among others. These adverse events along with rise in chronic diseases are anticipated to impel the adoption rate of enteral feeding devices in the country.
 

Germany held around 20% of revenue share in 2020 across the Europe enteral feeding devices market and is projected to cross USD 440 million by 2027 due to the high number of people suffering from cancer, growing geriatric population and rising prevalence of neurological disorders in the country. As per the Globocan (Global Cancer Observatory) in 2020, the number of people diagnosed with cancer in Germany was 628,519 and the number is further expected to grow in the coming period. According to the American Gastroenterology Association, the estimated prevalence of functional gastrointestinal disorders (FGIDs) in Germany was 36.5%. Moreover, high incidence of neurological disorders, gastrointestinal diseases and burden of healthcare costs associated with these diseases will augment the product acceptance.